Ipilimumab
Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab
December 14, 2017Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
FDA Expands Ipilimumab Indication to Include Pediatric Unresectable or Metastatic Melanoma
July 25, 2017The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.
Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival
June 05, 2017Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.
Prostate Cancer Response to Immunotherapy Improved With Combination Therapy
April 12, 2017Immunotherapy alone is not effective in prostate cancer; however, combining it with PD-1/PD-L1 and VISTA inhibitors is effective.
Ipilumumab Feasible for Recurrent Hematologic Cancers After Allogeneic Stem Cell Transplant
August 09, 2016Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).
Case Reports Show an Association Between Immune Checkpoint Inhibitors and Risk for Rheumatologic Disorders
July 11, 2016A small number of patients with cancer treated with immune checkpoint inhibitors may have higher-than-usual risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a case report on 13 patients has shown.
Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma
June 07, 2016Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
Surgery followed by ipilimumab improves survival for patients with melanoma
June 11, 2015An international study demonstrated that ipilimumab improves the relapse-free survival of patients with advanced stage melanoma who are rendered free of disease surgically but at high risk for relapse.
Nivolumab Demonstrates Consistent Adverse Event Profile for Recurrent Glioblastoma
May 31, 2015The adverse event profile of nivolumab with or without ipilimumab in patients with glioblastoma was encouraging.
Adjuvant ipilimumab improves survival after high-risk lymph node and melanoma resection
May 08, 2015Adjuvant ipilimumab significantly improves recurrence-free survival in patients with completely resected stage III melanoma at high risk of disease recurrence, but is also associated with a high rate of adverse events.
Immunotherapy shows clinical benefit in relapsed transplant recipients
January 06, 2015Almost half of patients with blood cancer who had relapsed following allogeneic stem cell transplantation benefitted from treatment with the immune checkpoint blocker ipilimumab.
Combination therapy for advanced melanoma found to increase survival
November 10, 2014Pairing ipilimumab with sargramostim gives patients about five extra months survival time for patients with advanced melanoma, researchers report.
Marker may predict response to ipilimumab in advanced melanoma
February 19, 2014Among patients with advanced melanoma, presence of higher levels of the protein VEGF in blood was associated with poor response to treatment with the immunotherapy ipilimumab.
Biomarker may help predict melanoma survival
February 06, 2014High pretreatment VEGF levels have been linked to lower survival after ipilimumab treatment.
ASCO: Combo antibody therapy effective for melanoma
May 17, 2013Findings from a phase I study of concurrent ipilimumab and nivolumab for advanced melanoma
A clearer role for radiotherapy in high-risk melanoma
August 16, 2012A new study suggests radiotherapy may hold clinical promise for the control of local lymph node bed recurrence of malignant melanoma.
Sign Up for Free e-newsletters
ONA Articles
- Acrylamide in Food and Cancer Risk (Fact Sheet)
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Skin Cancer Screening Programs: Are They Effective?
- Acrylamide in Food and Cancer Risk (Fact Sheet)
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Culturally Sensitive Navigation Bridges Some Care Gaps for Latino Adults With Advanced Cancer
- Nedaplatin vs Cisplatin for Malignancy-Induced MPE: Noninferior, Less Toxicity
- Prophylactic Cranial Irradiation in Small-Cell Lung Cancer: Update on Patient Selection, Efficacy and Outcomes
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening Programs: Are They Effective?
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |